Table I.
Clinical data | Total, n=424 | Hepatocellular type, n=239 (56.4%) | Cholestatic type, n=101 (23.8%) | Mixed type, n=84 (19.8%) | P-value |
---|---|---|---|---|---|
Age, years | 47.9±15.2 | 47.2±14.3 | 51.8±18.9 | 50.7±19.0 | 0.388 |
Male/female, cases | 155/269 | 86/121 | 30/71 | 39/75 | 0.882 |
Length of stay, days | 29.4±18.4 | 29.4±19.0 | 29.9±16.1 | 29.6±16.6 | 0.993 |
DILI duration, days | 16.2±12.2 | 16.6±11.9 | 13.9±13.6 | 14.4±13.5 | 0.866 |
Medication time, days | 72.6±62.1 | 77.6±65.4 | 46.6±40.1 | 47.6±41.3 | 0.198 |
Clinical indices on admission | |||||
ALT, U/l | 591.2±458.9 | 608.4±475.8 | 498.1±374.0 | 525.6±370.0 | 0.560 |
AST, U/l | 349.1±341.0 | 366.1±352.8 | 273.3±263.5 | 277.3±277.1 | 0.363 |
ALP, U/l | 208.5±146.4 | 165.2±104.9 | 415.6±149.8 | 402.9±145.9 | 0.000 |
TBiL, µmol/l | 83.1±64.1 | 77.6±65.3 | 85.2±68.4 | 89.8±68.2 | 0.397 |
PT, sec | 13.45±1.88 | 13.57±1.96 | 12.84±1.37 | 12.91±1.39 | 0.176 |
PTA, % | 97.11±23.77 | 95.09±23.24 | 114.65±16.26 | 105.8±24.86 | 0.002a |
INR | 1.02±0.20 | 1.04±0.21 | 0.96±0.13 | 0.97±0.13 | 0.186 |
Clinical indices at discharge | |||||
ALT, U/l | 35.83±31.29 | 28.63±19.45 | 29.67±19.67 | 37.27±33.19 | 0.442 |
AST, U/l | 28.48±15.36 | 26.06±12.18 | 26.33±12.56 | 28.97±15.96 | 0.661 |
ALP, U/l | 106.34±55.07 | 96.47±46.60 | 150.81±68.29 | 153.67±69.69 | 0.000a |
TBiL, µmol/l | 17.68±9.52 | 17.29±9.18 | 19.13±11.13 | 19.87±11.12 | 0.497 |
PT, sec | 13.49±1.33 | 13.43±1.43 | 13.00±0.77 | 14.32±1.72 | 0.319 |
PTA, % | 90.52±16.45 | 86.66±13.77 | 99.62±12.51 | 82.68±22.32 | 0.225 |
INR | 1.07±0.14 | 1.09±0.43 | 1.01±0.81 | 1.12±0.19 | 0.458 |
Compared with the hepatocellular and mixed type patients, ALP and PTA levels were the highest for cholestatic patients
P<0.05. DILI, drug-induced liver injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBiL, total bilirubin; PT, prothrombin time; PTA, prothrombin time activity; INR, international normalized ratio.